Although co-mutation of both ATM and TP53 is rare [59], co-mutation has been shown to occur in 2–3% of non-small cell lung cancer where it increases tumour mutation burden and correlates with better response to immune checkpoint therapy [60], suggesting additional opportunities for targeted therapy for ATM-deficient tumours. The gene discussed is ATM; the disease is non-small cell lung carcinoma.